WUXI BIO (02269) released its interim results for 2025, reporting the addition of 86 comprehensive projects in the first half, marking a historic high for the same period. This brings the total number of comprehensive projects to 864, further strengthening its leading position as having one of the industry's largest complex biologics pipelines. Among the newly signed projects, bispecific/multispecific antibodies and ADC accounted for over 70%, leading the two golden tracks of innovative biologics. The strong performance growth supports WUXI BIO's upward revision of its 2025 full-year revenue guidance to 14%-16%.

As of June 30, 2025, WUXI BIO's integrated platform hosts 67 clinical Phase III projects and 24 commercial production projects, with revenue increasing 24.9% year-over-year. Additionally, its research services have empowered over 50 molecular projects, with rights to receive future potential milestone payments and sales royalties, which will significantly enhance the company's long-term profit growth.

A molecule developed for GSK has entered the clinical stage, becoming the fourth TCE project empowered by WUXI BIO to reach clinical development. In terms of project orders, WUXI BIO's total unfinished orders exceed $20 billion, reaching $20.34 billion. The three-year unfinished order backlog has grown to $4.21 billion, indicating substantial near-term revenue growth prospects.